Auranofin (Ridaura, SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. Auranofin has anti-cancer activity and can completely inhibit bacterial growth at 1.2 μM. Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis. 金诺芬可在多个位点抑制白细胞活化途径，还可抑制人巨噬细胞、嗜碱性粒细胞和肺肥大细胞释放炎症介质。 金诺芬还可修饰IKKβ亚基5的Cys-179和参与氧化应激防御的硒酶硫氧还蛋白还原酶（TrxR），从而抑制人嗜中性粒细胞5-脂氧合酶和IKB激酶（IKK）。 金诺芬是一种改善病情的抗风湿药（DMARD），可用于研究抗OVCAR-3人卵巢癌细胞增殖作用。 Auranofin (Ridaura, SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. Auranofin has anti-cancer activity and can completely inhibit bacterial growth at 1.2 μM. Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis. Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.